Colchicine After Electrocardioversion for Atrial Fibrillation
Key facts
- Where
- Bad Krozingen, Dresden, Herne és Luebeck, NémetországSee the 4 sites
- Phase
- 3. fázis
Where in Németország
- University Medical Center Freiburg, University Heart CenterBad Krozingen, NémetországToborzás még nem indult
- Herzzentrum Dresden GmbH UniversitaetsklinikDresden, NémetországToborzás még nem indult
- Marien Hospital HerneHerne, NémetországToborzás még nem indult
- Universitaetsklinikum Schleswig-Holstein AöRLuebeck, NémetországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT05890664EU 2024-516033-12-00
- Record updated
- 2025. május 28.
- Original description
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.Read full original descriptionShow less
Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.
Inclusion: Age \>18 years; ECG-documented AF prior to ECV; Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV; Ability to give written informed consent.
Exclusion: Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV; Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole); Known intolerance or hypersensitivity to Colchicine; Serious gastrointestinal disease (severe gastritis or diarrhea); Clinically overt hepatic disease; Significant immunosuppression (e.g. due to transplantation or rheumatic disease); Severe renal disease (eGFR\< 30ml/min/1.73m2); AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV; Any other rhythm than AF before cardioversion; Any other absolute indication for Colchicine intake; Clinically significant blood dyscrasia (e.g., myelodysplasia); Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control; Life expectancy \<1 year.